Trial Outcomes & Findings for Comprehensive Evaluation of Ischemic Heart Disease Using MRI (NCT NCT01234870)

NCT ID: NCT01234870

Last Updated: 2014-09-26

Results Overview

The purpose of the study is to assess the incremental value of diagnostic performance using a fully-automated, motion-corrected (MC) first pass myocardial perfusion image acquisition protocol compared to images obtained under a non-corrected, breath-hold, shallow-breathing first pass myocardial perfusion image acquisition protocol in patients with suspected ischemic heart disease. The MR images resulting from two different image acquisition techniques, including Non-Corrected Breath-Hold Shallow-Breathing and Motion-Corrected, were assessed independently by two radiologists (average of 7 years of experience in reading cardiac MRI) using the American Heart Association modified 16 segment model and were evaluated using a four point Likert scale (1 = poor, 2 = fair, 3 = good, and 4 = excellent) for image quality

Recruitment status

COMPLETED

Study phase

PHASE2/PHASE3

Target enrollment

40 participants

Primary outcome timeframe

Cross sectional study; magnetic resonance images were obtained on all patients using two different acquisition methods.

Results posted on

2014-09-26

Participant Flow

Participant milestones

Participant milestones
Measure
Ischemic Heart Disease Patients
Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
Overall Study
STARTED
40
Overall Study
COMPLETED
40
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Adenosine
n=40 Participants
Adenosine (Adenoscan) will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins. adenosine: Adenosine will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins
Age, Continuous
60.9 years
STANDARD_DEVIATION 8.21 • n=99 Participants
Sex: Female, Male
Female
13 Participants
n=99 Participants
Sex: Female, Male
Male
27 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
6 Participants
n=99 Participants
Race (NIH/OMB)
White
30 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
32 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
6 Participants
n=99 Participants
Region of Enrollment
United States
40 participants
n=99 Participants
Body Mass Index (BMI)
29.57 kg/m^2
STANDARD_DEVIATION 5.83 • n=99 Participants

PRIMARY outcome

Timeframe: Cross sectional study; magnetic resonance images were obtained on all patients using two different acquisition methods.

The purpose of the study is to assess the incremental value of diagnostic performance using a fully-automated, motion-corrected (MC) first pass myocardial perfusion image acquisition protocol compared to images obtained under a non-corrected, breath-hold, shallow-breathing first pass myocardial perfusion image acquisition protocol in patients with suspected ischemic heart disease. The MR images resulting from two different image acquisition techniques, including Non-Corrected Breath-Hold Shallow-Breathing and Motion-Corrected, were assessed independently by two radiologists (average of 7 years of experience in reading cardiac MRI) using the American Heart Association modified 16 segment model and were evaluated using a four point Likert scale (1 = poor, 2 = fair, 3 = good, and 4 = excellent) for image quality

Outcome measures

Outcome measures
Measure
Ischemic Heart Disease Patients
n=40 Participants
Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
Magnetic Resonance Image Quality Rating
Motion Corrected Images
3.57 units on a likert scale
Standard Deviation 0.66
Magnetic Resonance Image Quality Rating
Non-Corrected Breath-Hold, Shallow-Breathing Image
2.55 units on a likert scale
Standard Deviation 0.81

SECONDARY outcome

Timeframe: 14 days

Adverse events relating to administration of adenosine during a coronary heart disease comprehensive cardiac MRI study.

Outcome measures

Outcome measures
Measure
Ischemic Heart Disease Patients
n=40 Participants
Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol
0 occurances of adverse events

Adverse Events

Adenosine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. James Carr

Northwestern University

Phone: (312)695-4218

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place